mp.weixin.qq.com·· 12 hours agoPickScore82
Sunvozertinib (ZEGFROVY) Launches in the US for EGFR exon20ins Non-Small Cell Lung Cancer
In brief
On October 23, 2026, Dizhe Pharmaceutical (Dizhe Cayman) announced that its global strategic partner AstraZeneca has commercially launched sunvozertinib tablets (ZEGFROVY) in the United States. The drug treats adults with locally advanced or metastatic NSCLC harboring confirmed EGFR exon20ins whose disease progressed on or who cannot tolerate prior platinum-based chemotherapy. The second/later-line monotherapy indication is now approved in both China and the US, and the first-line supplemental application has been accepted for review by the CDE and the FDA.
Why it matters
The material distinguishes the US-launched later-line indication from the first-line applications accepted in China and the US.
Source: mp.weixin.qq.com · mp.weixin.qq.com